Liver biopsy in a district general hospital: Changes over two decades

World Journal of Gastroenterology

Volumn 13, Issue 40, 2007, Pages 5336-5342

  Syn, Wing Kin ^a   Bruckner Holt, Caroline ^b   Farmer, Adam ^c   Howdle, Sarah ^b   Bateman, Jeffrey ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

Complication; District general; Indication; Liver biopsy; Non alcoholic fatty liver

Indexed keywords

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BILIARY CIRRHOSIS; BIOCHEMISTRY; BLOOD CLOTTING; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOLOGY; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PAIN; SEROLOGY; THROMBOCYTE; UNITED KINGDOM;

EID: 35248900874     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i40.5336     Document Type: Article

References (47)

1. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4: IV1-IV11
2. Sherlock S, Dooley J. Chapter 3: Biopsy of the Liver. In: Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th ed. Oxford, UK: Blackwell Science Ltd, 2002:37-44
3. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000; 95: 3206-3210
4. Office for National Statistics. Obesity among adults: by sex and NS-SeC, 2001: Social Trends 34. Available from: URL: http://www.statistics.gov.uk
5. Livingstone MB. Childhood obesity in Europe: a growing concern. Public Health Nutr 2001; 4: 109-116
6. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007; 369: 750-756
7. Ehtisham S, Barrett TG. The emergence of type 2 diabetes in childhood. Ann Clin Biochem 2004; 41:10-16
8. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917-923
9. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-3004
10. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36:437-441
11. Dixon AK, Nunez DJ, Bradley JR, Seymour CA. Failure of percutaneous liver biopsy: anatomical variation. Lancet 1987; 2: 437-439
12. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999; 34: 85-91
13. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-3014
14. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-199
15. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438
16. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80
17. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419
18. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356-1362
19. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970; 3: 371-407
20. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-761
21. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41
22. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109
23. Bianchi L. Liver biopsy in elevated liver functions tests? An old question revisited. J Hepatol 2001; 35: 290-294
24. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750
25. Caldwell SH, Hylton AI. The clinical outcome of NAFLD including cryptogenic cirrhosis. In: Farrell GC, George J, de la M. Hall P, McCullough AJ. Fatty Liver Disease: NASH and Related Disorders. Oxford, UK: Blackwell Publishing Ltd, 2005: 168-180
26. Akyüz F, Demir K, Ozdil S et al. The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2007; Epub ahead of print
27. Yamamoto M, Iwasa M, Iwata K, Kaito M, Sugimoto R, Urawa N, Mifuji R, Konishi M, Kobayashi Y, Adachi Y. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22: 498-503
28. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006; 13: 2889-2900
29. Lavoie JM, Gauthier MS. Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci 2006; 63:1393-1409
30. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-141
31. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307
32. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123
33. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96: 1037-1042
34. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007; 109: 718-726
35. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399-1402
36. Neuberger J. Primary biliary cirrhosis. In: O'Grady JG, Lake JR, Howdle PD, editors. Comprehensive Clinical Hepatology. Mosby, London: Harcourt Publishers Limited, 2000:17.1-17.13
37. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. Technology appraisal 2006 (106). Available from: URL:http://www.nice.org.uk/TA106
38. National Institute for Health and Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology appraisal 2004 (75). Available from: URL: http://www.nice.org.uk/TA75
39. Brandao C, Barone A, Carrilho F, Silva A, Patelli M, Caramori C, Focaccia R, Pereira L, Pedroso M, Tatsch F, Pessoa M. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat 2006; 13: 552-559
40. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500
41. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med 1993; 118: 150-153
42. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993; 118: 96-98
43. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-173
44. Farrell RJ, Smiddy PF, Pilkington RM, Tobin AA, Mooney EE, Temperley IJ, McDonald GS, Bowmer HA, Wilson GF, Kelleher D. Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 1999; 30: 580-587
45. Nobili V, Comparcola D, Sartorelli MR, Natali G, Monti L, Falappa P, Marcellini M. Blind and ultrasound-guided percutaneous liver biopsy in children. Pediatr Radiol 2003; 33: 772-775
46. Vautier G, Scott B, Jenkins D. Liver biopsy: blind or guided? BMJ 1994; 309: 1455-1456
47. Caturelli E, Giacobbe A, Facciorusso D, Bisceglia M, Villani MR, Siena DA, Fusilli S, Squillante MM, Andriulli A. Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. Am J Gastroenterol 1996; 91: 1318-1321